B-cell prolymphocytic leukemia (B-PLL) (published in 1998)
1998-10-01 Lucienne Michaux  , Lucienne Michaux   Affiliation1.Department of Hematology, Center for Human Genetics Cliniques Universitaires Saint Luc Avenue Hippocrate 10 1200 Brussels, Belgium
Clinics and Pathology
Disease
Phenotype stem cell origin
immunophenotypically, B-PLL is characterized by reactivity with pan B-cell markers CD19, CD20 and CD24;
B-PLL cells are distinct from B-CLL cells in that they express bright surface immunoglobulin, unfrequently express CD5, fail to form rosettes with mouse erythrocytes and react strongly with FMC7;
expression of CD22 is often observed whereas CD23 is usually not expressed
Epidemiology
Clinics
B-PLL is characterized by high white blood cell counts and splenomegaly without adenopathy;
bone marrow infiltration pattern is either diffuse or mixed;
blood data: elevated white blood cell counts with prolymphocytes representing more than 55% of the circulating lymphoid cells;
anemia and thrombocytopenia may be observed
Prognosis
Genes Involved and Proteins
Immunoglobulin gene rearrangements are always observed.
BCL-1 gene is involved in some cases bearing t(11;14)(q13;q32), with breakpoints located centrometric to the major translocation cluster.
Overall, abnormalities of P53 occur in 75% cases, representing the highest reported frequency in B-cell malignancies.
No CDKNL-2 or RB1 gene involvement has been documented so far.
C-MYC rearrangement has been described in PLL.
Bibliography
No bibliography items were found for this article.
Citation
Lucienne Michaux ; Lucienne Michaux
B-cell prolymphocytic leukemia (B-PLL) (published in 1998)
Atlas Genet Cytogenet Oncol Haematol. 1998-10-01
Online version: http://atlasgeneticsoncology.org/haematological/1860/b-cell-prolymphocytic-leukemia-(b-pll)-(published-in-1998)
